Mavacamten

Generic Name: Mavacamten

Brand Names: Camzyos

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₉N_₃O_₂

CAS Number: 1642288-47-8

Unique Ingredient Identifier: QX45B99R3J

Background: Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and ...

Indication: Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms by the FDA, Health Canada, and the EMA.

Associated Conditions: Symptomatic Obstructive Hypertrophic Cardiomyopathy

Associated Therapies: -

Clinical Trials

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy

Interventions: Drug: Mavacamten

First Posted Date: 2024-08-13

Last Posted Date: 2024-11-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 118

Registration Number: NCT06551129

Locations: 🇺🇸
Analysis Group Inc., Boston, Massachusetts, United States

A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Active, not recruiting

Conditions: Hypertrophic Cardiomyopathy

Interventions: Drug: Mavacamten

First Posted Date: 2024-08-12

Last Posted Date: 2024-08-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 685

Registration Number: NCT06549608

Locations: 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Active, not recruiting

Conditions: Hypertrophic Cardiomyopathy (HCM)

Interventions: Drug: Approved Hypertrophic Cardiomyopathy drug treatments
Drug: Mavacamten

First Posted Date: 2024-04-18

Last Posted Date: 2024-04-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 500

Registration Number: NCT06372457

Locations: 🇺🇸
IQVIA, Durham, North Carolina, United States

Real-World Effectiveness of Mavacamten in Canada

Not yet recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions: Drug: Mavacamten

First Posted Date: 2024-03-29

Last Posted Date: 2024-03-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT06338202

Locations: 🇨🇦
London Health Science Centre (LHSC), London, Ontario, Canada

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Phase 3

Recruiting

Conditions: Cardiomyopathy, Hypertrophic

Interventions: Drug: Placebo
Drug: Mavacamten

First Posted Date: 2024-02-12

Last Posted Date: 2024-12-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT06253221

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇮🇹
Istituto Giannina Gaslini, Genova, GE, Italy
🇫🇷
CHU Hopitaux de Bordeaux - Hopital Haut-Leveque, Pessac, France

and more 52 locations

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy

Interventions: Drug: Mavacamten

First Posted Date: 2023-11-27

Last Posted Date: 2024-11-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 600

Registration Number: NCT06146660

Locations: 🇰🇷
Local Institution - 0001, Seoul, Korea, Republic of
🇰🇷
Novotech Laboratory Korea Co., Ltd., Seoul, Korea, Republic of

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Phase 4

Recruiting

Conditions: Cardiomyopathy, Hypertrophic

Interventions: Drug: Mavacamten

First Posted Date: 2023-11-01

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 85

Registration Number: NCT06112743

Locations: 🇵🇱
Local Institution - 0094, Warszawa, Mazowieckie, Poland
🇺🇸
Local Institution - 0087, West Hollywood, California, United States
🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States

and more 86 locations

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy

Interventions: Drug: mavacamten

First Posted Date: 2023-09-05

Last Posted Date: 2024-11-06

Lead Sponsor: Michael Ayers

Target Recruit Count: 20

Registration Number: NCT06023186

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Mavacamten Pregnancy Surveillance Program

Recruiting

Conditions: Breastfeeding
Hypertrophic Cardiomyopathy
Pregnancy Related

Interventions: Drug: Mavacamten

First Posted Date: 2023-07-11

Last Posted Date: 2023-11-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT05939700

Locations: 🇺🇸
The Mavacamten Pregnancy Surveillance Program, PPD Inc, Wilmington, North Carolina, United States

A Study to Evaluate the Effects of Mavacamten in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Mavacamten

First Posted Date: 2023-02-09

Last Posted Date: 2023-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 84

Registration Number: NCT05719805

Locations: 🇺🇸
Local Institution - 0002, Saint Paul, Minnesota, United States
🇺🇸
Local Institution - 0001, Miami, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy